# US 2010/0166760 A1 · Methods of reducing phosphate absorption

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166760 A1
- Document ID: US20100166760A1
- Status: Published application
- Kind: A1
- Application number: 12/447,385
- Filed: 2007-10-23
- Published: 2010-07-01
- Earliest claimed: 2006-10-25
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Mark Cook; Martin Petkovich; Christian Helvig; Erica Hellestad; Keith Crawford
- Web page: https://patentgrep.com/patent/US20100166760A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 3/12: for electrolyte homeostasis
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/542: {oral/gastrointestinal}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

## Claims

### Claim 1

A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an IgY anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to Npt2B of SEQ ID NO:1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has a kidney disease.

### Claim 4 (depends on 3)

The method of claim 3, wherein the kidney disease is selected from end stage renal disease, acute renal failure, chronic renal failure, polycystic kidney disease, chronic kidney disease, acute tubular necrosis, an infection that reduces kidney function, and a urinary tract obstruction.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is receiving a vitamin D compound.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is obtained from an avian egg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody is administered with a phosphate binder.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the steps of measuring the serum phosphate concentration after the anti-intestinal Npt2B antibody is administered and comparing the concentration to that before the anti-intestinal Npt2B antibody is administered.

### Claim 9

A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to an epitope within amino acids 234-362 of SEQ ID NO:1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the anti-intestinal Npt2B antibody binds to an epitope within amino acids 245-340 of SEQ ID NO:1.

### Claim 11 (depends on 9)

The method of claim 9, wherein the anti-intestinal Npt2B antibody binds to an epitope within amino acids 252-330 of SEQ ID NO:1.

### Claim 12 (depends on 9)

The method of claim 9, wherein the subject is a human subject.

### Claim 13 (depends on 9)

The method of claim 9, wherein the subject has a kidney disease.

### Claim 14 (depends on 13)

The method of claim 13, wherein the kidney disease is selected from end stage renal disease, acute renal failure, chronic renal failure, polycystic kidney disease, chronic kidney disease, acute tubular necrosis, an infection that reduces kidney function, and a urinary tract obstruction.

### Claim 15 (depends on 9)

The method of claim 9, wherein the subject is receiving a vitamin D compound.

### Claim 16 (depends on 9)

The method of claim 9, wherein the antibody is an IgY antibody.

### Claim 17 (depends on 9)

The method of claim 9, wherein the antibody is administered with a phosphate binder.

### Claim 18 (depends on 9)

The method of claim 9, further comprising the steps of measuring the serum phosphate concentration after the anti-intestinal Npt2B antibody is administered and comparing the concentration to that before the anti-intestinal Npt2B antibody is administered.

### Claim 19

A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to an epitope within amino acids 429-485 of SEQ ID NO:1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anti-intestinal Npt2B antibody binds to an epitope within amino acids 445-480 of SEQ ID NO:1.

### Claim 21 (depends on 19)

The method of claim 19, wherein the anti-intestinal Npt2B antibody binds to an epitope within amino acids 455-474 of SEQ ID NO:1.

### Claim 22 (depends on 19)

The method of claim 19, wherein the subject is a human subject.

### Claim 23 (depends on 19)

The method of claim 19, wherein the subject has a kidney disease.

### Claim 24 (depends on 23)

The method of claim 23, wherein the kidney disease is selected from end stage renal disease, acute renal failure, chronic renal failure, polycystic kidney disease, chronic kidney disease, acute tubular necrosis, an infection that reduces kidney function, and a urinary tract obstruction.

### Claim 25 (depends on 19)

The method of claim 19, wherein the subject is receiving a vitamin D compound.

### Claim 26 (depends on 19)

The method of claim 19, wherein the antibody is an IgY antibody.

### Claim 27 (depends on 19)

The method of claim 19, wherein the antibody is administered with a phosphate binder.

### Claim 28 (depends on 19)

The method of claim 19, further comprising the steps of measuring the serum phosphate concentration after the anti-intestinal Npt2B antibody is administered and comparing the concentration to that before the anti-intestinal Npt2B antibody is administered.

### Claim 29

A method of reducing side effects of vitamin D therapy in a human comprising the step of:
administering orally to the subject (a) a vitamin D compound and (b) an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to Npt2B of SEQ ID NO:1 in an amount effective to reduce hyperphosphatemia induced by vitamin D therapy.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject has a kidney disease.

### Claim 31 (depends on 29)

The method of claim 29, wherein the human has a vitamin D deficiency.

### Claim 32 (depends on 29)

The method of claim 29, wherein the antibody is administered with a phosphate binder.

### Claim 33 (depends on 29)

The method of claim 29, further comprising the steps of measuring the serum phosphate concentration after the anti-intestinal Npt2B antibody is administered and comparing the concentration to that before the anti-intestinal Npt2B antibody is administered.
